At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 692 enrolled
Drug / intervention
Insulin Efsitora Alfa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
In Brief
A Phase 3 clinical trial evaluating Insulin Efsitora Alfa and Insulin Degludec for Type 1 Diabetes and Diabetes. Completed, enrolled 692 participants across 83 sites in 7 countries.
Detailed Summary
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Diabetes
CountriesArgentina, Japan, Poland, Puerto Rico, Slovakia, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartAug 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedJul 19, 2022
Enrollment StartAug 12, 2022
Primary CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.0 years ago
Interventions
Insulin Efsitora Alfadrug
Administered SC
Insulin Degludecdrug
Administered SC